Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Century Therapeutics, Inc.

An announcement from Century Therapeutics ( ($IPSC) ) is now available. Century Therapeutics reported its second-quarter 2026 results on August 12,...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IPSC	$2.11	+0.96%	300.38K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IPSC	$2.11	+1.0%	300.38K
3
4
5
6

IPSC

Get Century Therapeutics, Inc. Data in Excel

Get Century Therapeutics, Inc. Data in Excel